{"entity":{"type":"insider","cik":"0001880179","url":"/insider/0001880179","json_url":"/insider/0001880179.json","name":"DiBiase Mary","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":17,"first":"2022-02-14","last":"2025-01-27","span_basis":"filed_date"},"name_variants":[{"name":"DiBiase Mary","source":"filing","n_filings":17,"first_seen":"2022-02-14","last_seen":"2025-01-27"}],"transactions":[{"id":4633296,"accession":"0001628280-25-002706","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-25-002706","line_url":"/filing/0001628280-25-002706#line-2","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22258.0,"shares_display":"22,258","price_per_share":0.4535,"price_display":"0.45","price_state":"stated","total_value":10094.003,"total_display":"10,094.00","total_whole":"10,094","shares_owned_after":490980.0,"shares_owned_after_display":"490,980","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-24","filed_date":"2025-01-27","scope":"insider"},{"id":2049072,"accession":"0001628280-24-042542","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-24-042542","line_url":"/filing/0001628280-24-042542#line-2","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67695.0,"shares_display":"67,695","price_per_share":0.5662,"price_display":"0.57","price_state":"stated","total_value":38328.909,"total_display":"38,328.91","total_whole":"38,329","shares_owned_after":452060.0,"shares_owned_after_display":"452,060","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-07","filed_date":"2024-10-08","scope":"insider"},{"id":3059349,"accession":"0001628280-24-040128","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-24-040128","line_url":"/filing/0001628280-24-040128#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2642.0,"shares_display":"2,642","price_per_share":0.6577,"price_display":"0.66","price_state":"stated","total_value":1737.6434,"total_display":"1,737.64","total_whole":"1,738","shares_owned_after":289110.0,"shares_owned_after_display":"289,110","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-09","filed_date":"2024-09-11","scope":"insider"},{"id":2704024,"accession":"0001628280-24-010278","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-24-010278","line_url":"/filing/0001628280-24-010278#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15409.0,"shares_display":"15,409","price_per_share":0.882,"price_display":"0.88","price_state":"stated","total_value":13590.738,"total_display":"13,590.74","total_whole":"13,591","shares_owned_after":291752.0,"shares_owned_after_display":"291,752","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-11","filed_date":"2024-03-11","scope":"insider"},{"id":2992429,"accession":"0001628280-24-004288","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-24-004288","line_url":"/filing/0001628280-24-004288#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3683.0,"shares_display":"3,683","price_per_share":1.007,"price_display":"1.01","price_state":"stated","total_value":3708.781,"total_display":"3,708.78","total_whole":"3,709","shares_owned_after":307161.0,"shares_owned_after_display":"307,161","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-12","filed_date":"2024-02-12","scope":"insider"},{"id":7822059,"accession":"0001628280-23-036757","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-23-036757","line_url":"/filing/0001628280-23-036757#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67695.0,"shares_display":"67,695","price_per_share":0.73,"price_display":"0.73","price_state":"stated","total_value":49417.35,"total_display":"49,417.35","total_whole":"49,417","shares_owned_after":310844.0,"shares_owned_after_display":"310,844","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-01","filed_date":"2023-11-03","scope":"insider"},{"id":8025437,"accession":"0001628280-23-032065","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-23-032065","line_url":"/filing/0001628280-23-032065#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2642.0,"shares_display":"2,642","price_per_share":1.249,"price_display":"1.25","price_state":"stated","total_value":3299.858,"total_display":"3,299.86","total_whole":"3,300","shares_owned_after":147894.0,"shares_owned_after_display":"147,894","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-08","filed_date":"2023-09-12","scope":"insider"},{"id":8306272,"accession":"0001628280-23-024229","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-23-024229","line_url":"/filing/0001628280-23-024229#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":464.0,"shares_display":"464","price_per_share":1.89,"price_display":"1.89","price_state":"stated","total_value":876.96,"total_display":"876.96","total_whole":"877","shares_owned_after":150536.0,"shares_owned_after_display":"150,536","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-30","filed_date":"2023-07-05","scope":"insider"},{"id":8639621,"accession":"0001628280-23-023445","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-23-023445","line_url":"/filing/0001628280-23-023445#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":857.0,"shares_display":"857","price_per_share":1.93,"price_display":"1.93","price_state":"stated","total_value":1654.01,"total_display":"1,654.01","total_whole":"1,654","shares_owned_after":151000.0,"shares_owned_after_display":"151,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-23","filed_date":"2023-06-26","scope":"insider"},{"id":8268565,"accession":"0001628280-23-022480","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-23-022480","line_url":"/filing/0001628280-23-022480#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":857.0,"shares_display":"857","price_per_share":2.23,"price_display":"2.23","price_state":"stated","total_value":1911.11,"total_display":"1,911.11","total_whole":"1,911","shares_owned_after":151857.0,"shares_owned_after_display":"151,857","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-15","filed_date":"2023-06-16","scope":"insider"},{"id":8593222,"accession":"0001628280-23-007724","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-23-007724","line_url":"/filing/0001628280-23-007724#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18192.0,"shares_display":"18,192","price_per_share":0.84,"price_display":"0.84","price_state":"stated","total_value":15281.28,"total_display":"15,281.28","total_whole":"15,281","shares_owned_after":152714.0,"shares_owned_after_display":"152,714","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-10","filed_date":"2023-03-13","scope":"insider"},{"id":8616855,"accession":"0001628280-23-003758","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-23-003758","line_url":"/filing/0001628280-23-003758#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4348.0,"shares_display":"4,348","price_per_share":0.93,"price_display":"0.93","price_state":"stated","total_value":4043.64,"total_display":"4,043.64","total_whole":"4,044","shares_owned_after":170906.0,"shares_owned_after_display":"170,906","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-13","filed_date":"2023-02-15","scope":"insider"},{"id":6551786,"accession":"0001628280-22-023325","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-22-023325","line_url":"/filing/0001628280-22-023325#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1713.0,"shares_display":"1,713","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":177896.0,"shares_owned_after_display":"177,896","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-17","filed_date":"2022-08-19","scope":"insider"},{"id":6357438,"accession":"0001628280-22-018397","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-22-018397","line_url":"/filing/0001628280-22-018397#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1578.0,"shares_display":"1,578","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":179609.0,"shares_owned_after_display":"179,609","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-30","filed_date":"2022-07-01","scope":"insider"},{"id":6499409,"accession":"0001628280-22-018044","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-22-018044","line_url":"/filing/0001628280-22-018044#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":856.0,"shares_display":"856","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":181187.0,"shares_owned_after_display":"181,187","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-24","filed_date":"2022-06-27","scope":"insider"},{"id":6162200,"accession":"0001628280-22-017435","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-22-017435","line_url":"/filing/0001628280-22-017435#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":856.0,"shares_display":"856","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":182043.0,"shares_owned_after_display":"182,043","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-16","filed_date":"2022-06-17","scope":"insider"},{"id":6103263,"accession":"0001628280-22-002508","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-22-002508","line_url":"/filing/0001628280-22-002508#line-1","is_derivative":false,"issuer_cik":"0001501697","issuer_name":"X4 Pharmaceuticals, Inc","issuer_ticker":"XFOR","issuer_name_source":null,"issuer_url":"/issuer/0001501697","owner_cik":"0001880179","owner_name":"DiBiase Mary","owner_display_name":"DiBiase Mary","owner_url":"/insider/0001880179","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12545.0,"shares_display":"12,545","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":77899.0,"shares_owned_after_display":"77,899","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-11","filed_date":"2022-02-14","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":17,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":17,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":17},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001501697","name":"X4 Pharmaceuticals, Inc","url":"/issuer/0001501697","role":"Officer (Chief Operating Officer)","n_filings":17,"first_seen":"2022-02-14","last_seen":"2025-01-27"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001880179","retrieved_at":"2026-08-25T15:51:09+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}